To investigate the impact of TDP-43 on tau pathology in AD cases, we investigated 98 post-mortem human cases, including 26 controls without AD, 62 demented cases with moderate to high levels of ADNC (of these, 55 fulfilled the criteria for AD(LATE-NC+) and 12 for AD(LATE-NC-)) and 5 FTLD-TDP cases. This evidence concerns the gene MAPT and Alzheimer disease.